Synthetic Biologics Inc (NYSEMKT:SYN) posted its quarterly earnings results on Thursday. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.06) by $0.03, Bloomberg Earnings reports.

Shares of Synthetic Biologics (NYSEMKT:SYN) opened at 0.598 on Friday. The stock’s market cap is $72.89 million. Synthetic Biologics has a 12 month low of $0.41 and a 12 month high of $1.90. The stock has a 50 day moving average price of $0.57 and a 200 day moving average price of $0.64.

A number of research firms have issued reports on SYN. ValuEngine downgraded Synthetic Biologics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Zacks Investment Research downgraded Synthetic Biologics from a “buy” rating to a “hold” rating in a research report on Friday, April 7th. Finally, William Blair reissued an “outperform” rating and set a $5.00 price target on shares of Synthetic Biologics in a research report on Monday, May 22nd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $4.46.

COPYRIGHT VIOLATION WARNING: This story was reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/08/05/synthetic-biologics-inc-syn-issues-earnings-results.html.

A number of institutional investors have recently bought and sold shares of SYN. Norges Bank acquired a new position in Synthetic Biologics during the fourth quarter valued at approximately $356,000. LMR Partners LLP acquired a new position in Synthetic Biologics during the second quarter valued at approximately $194,000. Creative Planning increased its position in Synthetic Biologics by 65.4% in the second quarter. Creative Planning now owns 177,000 shares of the company’s stock valued at $100,000 after buying an additional 70,000 shares during the last quarter. UBS Group AG increased its position in Synthetic Biologics by 10.3% in the first quarter. UBS Group AG now owns 214,357 shares of the company’s stock valued at $135,000 after buying an additional 20,038 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in Synthetic Biologics by 3.1% in the first quarter. Bank of New York Mellon Corp now owns 263,598 shares of the company’s stock valued at $166,000 after buying an additional 7,962 shares during the last quarter.

About Synthetic Biologics

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Earnings History for Synthetic Biologics (NYSEMKT:SYN)

Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.